Wall Street closes at a record for the first time since end of January
Investing.com - Benchmark reiterated a Buy rating and $60.00 price target on Omnicell (NASDAQ:OMCL) shares following an investor meeting with the company’s CFO. The stock has declined 15% over the past week to $35.10, though Wall Street analysts maintain a consensus price target range of $49 to $70. According to InvestingPro analysis, the company appears undervalued at current levels, with a Fair Value of $54.29.
Analyst Bill Sutherland cited the company’s multi-year opportunity for accelerating revenue growth and expanding margins driven by Titan XT, the next generation automated dispensing cabinet, and Omnisphere, the cloud-based platform integrating health system ADCs and connected devices.
CFO Baird Radford said the company’s non-GAAP EBITDA margin can return to pre-pandemic levels in the high-teens through improved pricing, tighter management of labor and component costs, and operating leverage. Radford guided to non-GAAP EBITDA growing at about twice the pace of mid-single-digit revenue guidance this year.
Benchmark expects several years of double-digit revenue growth and earnings growth that should be more than twice that as the cycle develops. Omnisphere will have subscription pricing determined by applications utilized and the number of connected devices. This optimistic outlook aligns with InvestingPro data showing three analysts have recently revised earnings upwards, with net income expected to grow this year. For deeper insights, investors can access the comprehensive Pro Research Report covering OMCL and 1,400+ other US equities.
Radford said Omnicell is preparing to provide financing or leasing for some customers for the first time, which will put the company on more level footing with the other competitor in the duopoly.
In other recent news, Omnicell Inc. reported its fourth-quarter 2025 earnings, which showed a miss in earnings per share (EPS) expectations but a slight surpass in revenue forecasts. The company’s EPS was $0.40, falling short of the anticipated $0.50, representing a 20% shortfall. However, revenue reached $314 million, slightly above the forecast of $313.39 million. In addition to the earnings report, Benchmark reiterated a Buy rating on Omnicell, maintaining a price target of $60.00. This decision followed an investor meeting with Omnicell’s CFO, where the focus was on the company’s product cycle outlook. Analyst Bill Sutherland highlighted the multi-year opportunity for revenue growth and margin expansion driven by Titan XT and Omnisphere. These developments indicate ongoing interest and analysis from investment firms.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.